<DOC>
	<DOCNO>NCT00375713</DOCNO>
	<brief_summary>Korean double-blind non-inferiority study asses efficacy ( measure responder rate pruritus severity score patient visit 4 end-of-treatment visit 2 week treatment period ) safety Xyzal速 Zyrtec速 subject suffer dermatitis eczema pruritus symptom</brief_summary>
	<brief_title>Randomized Phase III Study Evaluate Efficacy Safety Xyzal速 ( Levocetirizine ) v Zyrtec速 ( Cetirizine ) Subjects With Dermatitis Eczema</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Levocetirizine</mesh_term>
	<mesh_term>Cetirizine</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>Subjects diagnose atopic dermatitis , contact dermatitis , prurigo , pruritus dermatitis eczema Subjects require agree concomitant use topical steroid preparation . Subjects minimum level pruritus use topical hydrocortisone run period Written inform consent sign dated subject/legal guardian Female subject childbearing potential eligible use medically accept contraceptive method negative pregnancy test . Subjects know hypersensitivity cetirizine levocetirizine Any clinically significant condition might interfere treatment evaluation , efficacy safety Have use forbidden concomitant medication respect adequate washout period define protocol</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Dermatitis</keyword>
	<keyword>Eczema</keyword>
	<keyword>Pruritus</keyword>
	<keyword>Xyzal</keyword>
	<keyword>Zyrtec</keyword>
	<keyword>Levocetirizine</keyword>
	<keyword>Cetirizine</keyword>
</DOC>